Central atropine-like toxicity in combined psychotropic drug administration.
D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D010276:Parasympatholytics / Q000008:administration & dosage* / Q000009:adverse effects; D010640:Phenothiazines; D010830:Physostigmine; D010919:Placebos; D011605:Psychoses, Substance-Induced / Q000209:etiology*; D012559:Schizophrenia / Q000188:drug therapy*
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D010276:Parasympatholytics; D010640:Phenothiazines; D010919:Placebos; D010830:Physostigmine